Cargando…

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer

Following definitive chemoradiation for anal squamous cell carcinoma (ASCC), patients face a variety of chronic issues including: bowel dysfunction, accelerated bone loss, sexual dysfunction, and psychosocial distress. The increasing incidence of this disease, high cure rates, and significant long-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savoie, Marissa B., Laffan, Angela, Brickman, Cristina, Daniels, Bevin, Levin, Anna, Rowen, Tami, Smith, James, Van Blarigan, Erin L., Hope, Thomas A., Berry-Lawhorn, J. Michael, Anwar, Mekhail, Van Loon, Katherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737598/ https://www.ncbi.nlm.nih.gov/pubmed/31510960 http://dx.doi.org/10.1186/s12885-019-6053-y

Ejemplares similares

Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer
por: Susko, Matthew S., et al.
Publicado: (2021)

Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A population-based study
por: Wu, Yinhang, et al.
Publicado: (2020)

Vitamin D Levels in Patients with Colorectal Cancer and Matched Household Members
por: Savoie, Marissa B., et al.
Publicado: (2019)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Long-Term Outcomes of Chemoradiation for Anal Cancer Patients
por: Kim, Hun Jin, et al.
Publicado: (2013)

Socioeconomic disparities in timeliness of care and outcomes for anal cancer patients
por: Ahmad, Tessnim R., et al.
Publicado: (2019)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
por: Yoder, Alison K., et al.
Publicado: (2021)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis
por: Koerber, Stefan Alexander, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Penile Mondor's disease in a patient treated with radical chemoradiation for anal cancer
por: Pittaka, Maria, et al.
Publicado: (2017)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
por: Northover, J, et al.
Publicado: (2010)

Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma
por: Provencher, Sawyna, et al.
Publicado: (2010)

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019)

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
por: Dewas, Claire Vautravers, et al.
Publicado: (2012)

Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer
por: Hernandez, Sharia, et al.
Publicado: (2023)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy
por: Silva, Ninoska N., et al.
Publicado: (2012)

Quantification of tumour heterogeneity and glucose metabolism on pre-chemoradiation PET/CT predicts survival in anal cancer
por: Afaq, A, et al.
Publicado: (2015)

Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database
por: Bian, Shelly X., et al.
Publicado: (2020)

Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study
por: Chu, William, et al.
Publicado: (2023)

Oncology patients’ perceptions of and experiences with COVID-19
por: Miaskowski, Christine, et al.
Publicado: (2020)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

A Case Report of an Early Response to Definitive Chemoradiation for Esophageal Carcinoma Cuniculatum
por: Long, David E., et al.
Publicado: (2020)

Definitive Chemoradiation With Dose Escalation for Locally Advanced Gastric Cancer: Case Studies
por: Anthony, Michelle, et al.
Publicado: (2020)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Factors predictive of parametrial boost in patients with cervical cancer treated with definitive chemoradiation
por: Jamora, Kurl E., et al.
Publicado: (2022)

Gastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation
por: Albana, Jasen, et al.
Publicado: (2022)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]
por: Casadei-Gardini, A, et al.
Publicado: (2019)

Towards harmonisation of case definitions for eight work-related musculoskeletal disorders - an international multi-disciplinary Delphi study
por: Tamminga, Sietske J., et al.
Publicado: (2021)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma
por: Grave, Athénaïs, et al.
Publicado: (2022)

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
por: Adenis, Antoine, et al.
Publicado: (2013)

Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation
por: Schernberg, Antoine, et al.
Publicado: (2017)

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer
por: Vogel, Jennifer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_13qfi9evcmhje6cblr7tdhf8aq